Patents by Inventor Ernest Terwilliger

Ernest Terwilliger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods that Enhance Articular Cartilage Repair
    Publication number: 20080031819
    Abstract: In general, this invention relates to compositions and methods useful in enhancing articular cartilage repair by providing for the sustained release of growth factors to articular cartilage cells to induce cell proliferation and extracellular matrix synthesis.
    Type: Application
    Filed: June 9, 2005
    Publication date: February 7, 2008
    Applicant: Beth Israel Deaconess Medical Center
    Inventors: Ernest Terwilliger, Magali Cucchiarini
  • Vector comprising a replication competent HIV-1 provirus and a heterologous gene
    Patent number: 6033902
    Abstract: A vector comprising an HIV segment and a heterologous gene segment, which produces a replication competent and an infective HIV virus is disclosed. When the heterologous gene is a marker gene, the spread of the virus can be observed in both in vitro and in vivo systems. The use of this vector in establishing methods for screening anti-viral compounds is also disclosed.
    Type: Grant
    Filed: December 8, 1992
    Date of Patent: March 7, 2000
    Assignee: Dana-Farber Cancer Institute
    Inventors: William A. Haseltine, Ernest Terwilliger
  • Cis-acting repression sequences, cis-acting antirepression sequences, vectors, methods of preparation and use
    Patent number: 5604114
    Abstract: Cis-acting repression sequences which are able to provide a cis-acting inhibitory effect on the expression of a gene when placed downstream of the gene in its untranslated message are dislcosed. Cis-acting anti-repression sequences which can relieve the cis-acting repression in the presence of the art gene product are also disclosed. These sequences correspond to a sufficient number of nucleotides from the HIV-I, HIV-2, STLV-3 or HTLV-IV genomes to provide the repression or anti-repression effects. The use of the sequences in vectors and systems to control the expression of a desired gene product is also described.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: February 18, 1997
    Assignee: Dana-Farber Cancer Institute
    Inventors: William A. Haseltine, Craig A. Rosen, Joseph G. Sodroski, Ernest Terwilliger, Wei C. Goh
  • Sequences containing the vpu gene and vectors therefore methods of preparation and use
    Patent number: 5288640
    Abstract: DNA segments encoding the vpu gene and a vector encoding the vpu gene are disclosed. These sequences containing the vpu gene can be used to express a protein that has antigenic determinants that can be used to screen for people having the HIV-1 virus.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: February 22, 1994
    Assignee: Dana Farber Cancer Institute
    Inventors: William A. Haseltine, Ernest Terwilliger, Eric Cohen
  • Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use
    Patent number: 5043262
    Abstract: A protein having molecular weight of approximately 16 kD which is also cleaved into a protein having a molecular weight of 15 kD is disclosed. This protein is referred to as viral protein U and produced by the vpu gene. It is disclosed that this protein has antigenic determinants and can be used to screen for people having the HIV-1 virus.
    Type: Grant
    Filed: May 12, 1988
    Date of Patent: August 27, 1991
    Assignee: Dana Farber Cancer Institute
    Inventors: William A. Haseltine, Ernest Terwilliger, Eric Cohen